Immunotherapy containing antibody bapineuzumab in people with mild to moderate Alzheimer's disease lead to fall in a cerebrospinal fluid biomarker, which may indicate downstream effects on the degenerative process, states report published Online First by IArchives of Neurology/I, a JAMA Network publication.
Alzheimer disease (AD) is a progressive neurodegenerative disease characterized by, among other things, deposits of extracellular (and) #946;-amyloid ( (and) #913; (and) #946;) plaques and intraneuronal ...
Immunotherapy containing antibody bapineuzumab in people with mild to moderate Alzheimer's disease lead to fall in a cerebrospinal fluid biomarker, which may indicate downstream effects on the degenerative process, states report published Online First by IArchives of Neurology/I, a JAMA Network publication.
Alzheimer disease (AD) is a progressive neurodegenerative disease characterized by, among other things, deposits of extracellular (and) #946;-amyloid ( (and) #913; (and) #946;) plaques and intraneuronal ...